![Timothy E. Woenker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Timothy E.
Woenker is currently the Chief Operating Officer & Director at Novilytic LLC.
Actieve functies van Timothy E. Woenker
Bedrijven | Functie | Begin |
---|---|---|
Novilytic LLC
![]() Novilytic LLC Medical/Nursing ServicesHealth Services Novilytic LLC is a private company that focuses on the pharmaceutical bioreactor market. The company supply kits that enable molecular recognition and quantification, which were developed and validated in collaboration with pharmaceutical pilot partners and customers. The company is based in West Lafayette, IN. Novilytic has worked on a number of SBIR grants through the National Institute of Health and its associated institutes. The company is backed by more than 10 patents (and two pending), partnerships with multiple analytical instrument companies, 2 pharmaceutical consortiums, and analytical science universities. The company's technology helps ensure quality and consistency by recognizing molecular structure early and often, which saves time and reduces purification costs. The CEO of the company is Paul C. Dreier. | Operationeel Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Novilytic LLC
![]() Novilytic LLC Medical/Nursing ServicesHealth Services Novilytic LLC is a private company that focuses on the pharmaceutical bioreactor market. The company supply kits that enable molecular recognition and quantification, which were developed and validated in collaboration with pharmaceutical pilot partners and customers. The company is based in West Lafayette, IN. Novilytic has worked on a number of SBIR grants through the National Institute of Health and its associated institutes. The company is backed by more than 10 patents (and two pending), partnerships with multiple analytical instrument companies, 2 pharmaceutical consortiums, and analytical science universities. The company's technology helps ensure quality and consistency by recognizing molecular structure early and often, which saves time and reduces purification costs. The CEO of the company is Paul C. Dreier. | Health Services |